KRAS and non-small cell lung carcinoma: AMG510 (Sotorasib) and MRTX849 (Adagrasib) were recently approved for the treatment of non-small cell lung cancer (NSCLC) carrying the KRASG12C mutation43, indicating that KRAS is no longer considered clinically undruggable.